Skip NavigationSkip to Content
Return Return to Search Results

Ribose modified nucleosides and nucleotides as ligands for purine receptors

  1. Author:
    Jacobson, K. A.
    Ravi, R. G.
    Nandanan, E.
    Kim, H. S.
    Moro, S.
    Kim, Y. C.
    Lee, K.
    Barak, D.
    Marquez, V. E.
    Ji, X. D.

  2. Author Address

    NIDDK, Mol Recognit Sect, LBC, NIH, Bethesda, MD 20902 USA. NIDDK, Mol Recognit Sect, LBC, NIH, Bethesda, MD 20902 USA. NCI, Med Chem Lab, Frederick, MD 21701 USA. Jacobson KA NIDDK, Mol Recognit Sect, LBC, NIH, Bethesda, MD 20902 USA.
    1. Year: 2001
  2. Journal: Nucleosides Nucleotides & Nucleic Acids
    1. 20
    2. 4-7
    3. Pages: 333-341
  4. Type of Article: Article
  1. Abstract:

    Molecular modeling of receptors for adenosine and nucleotide (P2) receptors with docked ligand, based on mutagenesis, was carried out. Adenosine 3',5'-bisphosphate derivatives act as selective P2Y(1) antagonists/partial agonists. The ribose moiety was replaced with carbocyclics, smaller and larger rings, conformationally constrained rings, and acyclics, producing compounds that retained receptor affinity. Conformational constraints were built into the ribose rings of nucleoside and nucleotide ligands using the methanocarba approach, i.e. fused cyclopropane and cyclopentane rings in place of ribose, suggesting a preference for the Northern (N) conformation among ligands for P2Y(1) and A(1) and A(3)ARs.

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel